article thumbnail

Cipla Vs Dr. Reddy’s Laboratories – Financials, Future Plans & More

Trade Brains

It is the world’s largest supplier of generic medicine, in terms of volume with a 20% market share. Following global demand, Cipla has deepened its portfolio for the US markets with continued traction in the respiratory franchise and expansion of its peptide portfolio with increased market share in the Company’s first Lanreotide injection.

article thumbnail

No Fear

Inside Information

The reaction to the online portfolio management solutions (aka the “robos”) generated the same kind of existential chill down the spine that the newfangled software thing did back in the day; people were once again fearful that a computer would replace them. Real advisors didn’t need that fancy stuff.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

High EPS Stocks In India – Stocks To Watch In 2023

Trade Brains

Some investors go for high EPS stocks in order to decrease the underlying volatility of their portfolio. Operating Profit Margin 20.20% Page Industries was established in 1994 as a licensed manufacturer, distributor, and marketer of Jockey International’s products in India. 42,500 EPS ₹613 Stock P/E 62.1 RoCE 67.2% RoCE 38.4%

article thumbnail

Transcript: Marta Norton

The Big Picture

She has a fascinating career, starting a PLS working away up as an analyst and eventually, head of outcome-based strategies for Morningstar, eventually rising from that position and portfolio manager to Chief Investment Officer. Let me give you some background on Morningstar Managed Portfolios. I saw how personal money is.

Portfolio 130
article thumbnail

Fundamental Analysis Of Sun Pharma – Financials & More Details

Trade Brains

These divisions have been arranged geographically and the company has a different product portfolio across these divisions. Sun Pharma in-licensed and commercialised an anti-acne product in the US market. We’ll read more about this in the next section of our fundamental analysis of Sun Pharma. making it a leader in the chronic segment.

article thumbnail

Should the CFP Board police financial advisor “bad apples”? The debate continues! (Part Two)

Sara Grillo

I do believe it should be different regulated differently from portfolio management, which is the typical definition of the registered investment advisor, but that it shouldn’t be the CFP Board that is controlling the regulatory environment for financial planners. Grillo: Next question. Well, we’ve kind of covered this already.

CFP 59
article thumbnail

Transcript: Gretchen Morgenson

The Big Picture

But the doctors that I have spoken to in emergency medicine say that’s absolutely not the case. MORGENSON: This is a $64 trillion question, Barry, and I would love for you to ask every State Attorney General, for instance, why haven’t you gone after for-profit medicine? We’re going to help you make more money.

Insurance 141